Tag: R-Pharm

High Aseptics: R-Opra Launches Complex Oncology Drug Production in Moscow

The Moscow-based R-Opra plant (part of the R-Pharm Group) has transitioned to the industrial production of sterile dosage forms....

GEROPHARM and R-PHARM Pharmaceutical Plant in Azerbaijan Sign Partnership Agreement for Insulin Localisation

GEROPHARM and OOO “R-Pharm” (member of R-Pharm Group of Companies) have announced a strategic partnership to localise the production of medicines for the treatment of socially significant diseases in Azerbaijan.

Markus Soeder: Sputnik V vaccine project in Bavaria is closed

Bavaria will block the production of Russia's Sputnik COVID-19 vaccine even if it is approved by the European Medicines...

Phase 3 clinical trial results of Coronavir (favipiravir) published in US Journal

The American Journal of Translational Research has published successful results of the Phase 3 clinical trial of Coronavir (INN: favipiravir). This study aimed to evaluate the efficacy...

R-Pharm has supplied to the regions a medicine for treatment of drug-resistant tuberculosis

The first three batches, more than 11,000 packs, of the drug Deltyba are ready for shipment to Russian healthcare facilities. The medicine...

R-Pharm presented results of phase III global research program for rheumatoid arthritis drug, novel IL-6 inhibitor Olokizumab

In the framework of the annual ACR Convergence 2021, R-Pharm Group presented successful results of olokizumab in two randomized...

R-Pharm presented results of phase III global research program – CREDO

In the framework of the annual ACR Convergence 2021, R-Pharm Group presented successful results of olokizumab in two randomized clinical trials of phase III global research program —...

Russian Health Ministry recommends RA drug olokizumab for patients with COVID-19 of any severity

The Ministry of Health of the Russian Federation has issued the 12th version of the Temporary guidelines for the...

The combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth

R-Pharm Group, the Russian Direct Investment Fund (RDIF) and AstraZeneca announce preliminary virus neutralizing activity results of combined use...

R-Pharm earned runner-up in BRICS Solutions Awards 2021

R-Pharm`s project on the development of olokizumab has been declared as the Runner-up in the category “Good Health and...

R-Pharm and Frontier Biotech will provide Russia with a new drug for the treatment of HIV

Aikening™ is a new fusion inhibitor. It is the first and only long-acting injectable (as IV infusion QW) available as a dual therapy for treatment-experienced patients with HIV-1 replication.

COVID-19 pathogenetic treatment is approved as an additional indication for olokizumab

Approval for a new indication will help healthcare professionals make streamlined decisions to administer preemptive anticytokine therapy.